PACBPACIFIC BIOSCIENCES OF CALI...

Nasdaq pacb.com


$ 1.47 $ 0.09 (6.52 %)    

Friday, 26-Apr-2024 15:59:56 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 1.47
$ 1.44
$ 0.00 x 0
$ 0.00 x 0
$ 1.36 - $ 1.53
$ 1.25 - $ 14.55
7,986,911
na
372.83M
$ 2.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-03-2023 09-30-2023 10-Q
3 08-04-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-05-2022 06-30-2022 10-Q
8 05-06-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-05-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 02-26-2021 12-31-2020 10-K
14 11-03-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 02-28-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-03-2019 03-31-2019 10-Q
21 02-26-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-03-2018 06-30-2018 10-Q
24 05-02-2018 03-31-2018 10-Q
25 02-26-2018 12-31-2017 10-K
26 11-02-2017 09-30-2017 10-Q
27 08-02-2017 06-30-2017 10-Q
28 05-05-2017 03-31-2017 10-Q
29 03-06-2017 12-31-2016 10-K
30 11-04-2016 09-30-2016 10-Q
31 08-04-2016 06-30-2016 10-Q
32 05-05-2016 03-31-2016 10-Q
33 03-11-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-05-2015 03-31-2015 10-Q
37 03-12-2015 12-31-2014 10-K
38 11-05-2014 09-30-2014 10-Q
39 08-05-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-downgrades-pacific-biosciences-to-neutral

JP Morgan analyst Rachel Vatnsdal downgrades Pacific Biosciences (NASDAQ:PACB) from Overweight to Neutral.

 goldman-sachs-maintains-neutral-on-pacific-biosciences-lowers-price-target-to-25

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target f...

 bernstein-maintains-outperform-on-pacific-biosciences-lowers-price-target-to-25

Bernstein analyst Eve Burstein maintains Pacific Biosciences (NASDAQ:PACB) with a Outperform and lowers the price target fro...

 goldman-sachs-downgrades-pacific-biosciences-to-neutral-lowers-price-target-to-25

Goldman Sachs analyst Matthew Sykes downgrades Pacific Biosciences (NASDAQ:PACB) from Buy to Neutral and lowers the price ta...

 scotiabank-maintains-sector-outperform-on-pacific-biosciences-lowers-price-target-to-8

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:PACB) with a Sector Outperform and lowers the price tar...

 td-cowen-maintains-buy-on-pacific-biosciences-lowers-price-target-to-25

TD Cowen analyst Daniel Brennan maintains Pacific Biosciences (NASDAQ:PACB) with a Buy and lowers the price target from $12 ...

 why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket

Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter results.

 sp-500-edges-lower-pacbio-shares-plunge

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.0...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 gold-moves-higher-morgan-stanley-earnings-top-views

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded up 0...

 dow-gains-over-100-points-bank-of-america-posts-upbeat-profit

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market ...

 barclays-maintains-equal-weight-on-pacific-biosciences-lowers-price-target-to-3

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and lowers the price target fr...

 goldman-sachs-maintains-buy-on-pacific-biosciences-lowers-price-target-to-7

Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Buy and lowers the price target from ...

 estonia-national-biobank-selects-pacbio-to-sequence-10000-whole-genomes

HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine an...

 canaccord-genuity-maintains-buy-on-pacific-biosciences-lowers-price-target-to-10

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:PACB) with a Buy and lowers the price target fro...

 top-5-health-care-stocks-which-could-rescue-your-portfolio-in-march

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION